Clinical outcomes, survival, and predictors in lower-risk myelodysplastic syndrome patients treated with cyclosporine A

CONCLUSION: CSA is a safe treatment and can significantly improve cytopenias in a substantial proportion of patients with MDS, especially in individuals with hypocellular bone marrow. However, CSA is not associated with PFS or OS.PMID:38368853 | DOI:10.1159/000537773

Source: Acta Haematologica - February 18, 2024 Category: Hematology Authors: Yingjia Lu Lina Zhang Weiying Qu Zhou Feng Yuan Deng Lin Zhao Source Type: research